High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura(National Center for Geriatrics and Gerontology), Katsuhiko Yanagisawa(National Center for Geriatrics and Gerontology), Koichi Tanaka(Shimadzu (Japan)), Katsumi Matsuzaki(Kyoto University), James D. Doecke(Royal Brisbane and Women's Hospital), Christopher C. Rowe(The University of Melbourne), Naoki Kaneko(University of California, Los Angeles), Colin L. Masters(Mental Health Research Institute), Victor L. Villemagne(The University of Melbourne), Ralph N. Martins(Edith Cowan University), Yutaka Arahata(National Center for Geriatrics and Gerontology), Kenji Ishii(Tokyo Metropolitan Institute of Gerontology), Shinichi Iwamoto, Kazunari Ishii(Hyogo Brain and Heart Center), Christopher Fowler(Florey Institute of Neuroscience and Mental Health), Taisuke Tomita(The University of Tokyo), Kengo Ito(National Center for Geriatrics and Gerontology), Vincent Doré(Australian e-Health Research Centre), Takashi Kato(National Center for Geriatrics and Gerontology), Qiao‐Xin Li(The University of Melbourne)
Cited by 1,715
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k
Alzheimer's disease
|Nature Reviews Disease Primers|2015|1.8k